Auregen Appoints Scott Lauder, Ph.D., As Chief Technology Officer

Mar 26, 2025•4 months ago

Position

Chief Technology Officer

Company

Auregen Biotherapeutics

Scott Lauder

CambridgeTherapeuticsBiotechnologyHealth Care

Description

Auregen Biotherapeutics has announced the appointment of Scott Lauder, Ph.D., as Chief Technology Officer. Dr. Lauder brings deep expertise in innovative technologies and biologic modalities, and will play a crucial role in advancing the Phase 1/2 study for AUR-201, the company's first-in-class therapeutic ear replacement for people with microtia.

Company Information

Company

Auregen Biotherapeutics

Location

Cambridge, Massachusetts, United States

About

Auregen is a pioneering clinical-stage company developing precision approaches to restore functional anatomy with cartilage cell therapy. The company focuses on creating living tissue through GMP-compliant autologous cell expansion, with the aim of reducing the potential for rejection risk or donor supply dependency.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Scott hidden